What it's for (Indications)
- Ertugliflozin + sitagliptin, represented by brand examples like Guja Sit, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- This combination therapy is designed for patients who are inadequately controlled on ertugliflozin or sitagliptin alone, or those already treated with both agents as separate tablets.
- The dual mechanism of action targets different physiological pathways involved in glucose homeostasis, offering comprehensive blood glucose management.
- It is crucial to emphasize that this medication is not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical recommended dosage for ertugliflozin + sitagliptin fixed-dose combination is one tablet once daily in the morning, with or without food. Available strengths usually combine ertugliflozin 5 mg with sitagliptin 100 mg, or ertugliflozin 15 mg with sitagliptin 100 mg. Dosage adjustments are critical in patients with renal impairment. For patients with an estimated glomerular filtration rate (eGFR) between 30 and less than 60 mL/min/1.73 m², the dose of ertugliflozin should not exceed 5 mg daily. This combination is contraindicated in patients with severe renal impairment, end-stage renal disease (ESRD), or those on dialysis, as the efficacy of ertugliflozin is reduced and sitagliptin requires significant dose reduction in such conditions. Healthcare professionals must assess renal function prior to initiation and periodically thereafter. |
Safety & Warnings
Common Side Effects
- Common side effects associated with ertugliflozin + sitagliptin include genital mycotic infections (e.
- g.
- , vulvovaginal candidiasis, balanitis), urinary tract infections, nasopharyngitis, headache, and increased urination.
- More serious, though less frequent, adverse reactions warranting immediate medical attention include diabetic ketoacidosis (DKA), especially in patients with acute illness or surgery; acute kidney injury; hypotension or volume depletion; necrotizing fasciitis of the perineum (Fournier's gangrene); pancreatitis (with symptoms like severe abdominal pain); severe hypersensitivity reactions (e.
- g.
- , anaphylaxis, angioedema, Stevens-Johnson syndrome); and bullous pemphigoid.
- Patients should be educated on the signs and symptoms of these serious conditions and advised to seek prompt medical evaluation if they occur.
- Regular monitoring for adverse effects is essential during treatment.
Serious Warnings
- Black Box Warning: While ertugliflozin + sitagliptin does not carry an FDA-mandated Black Box Warning, several serious safety concerns warrant prominent attention for healthcare providers and patients. These 'Serious Warnings' include the risk of diabetic ketoacidosis (DKA), which can occur even with normal or near-normal blood glucose levels and may necessitate hospitalization. There is also a risk of acute kidney injury, particularly in patients susceptible to volume depletion. Necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but severe and potentially life-threatening bacterial infection, has been reported with SGLT2 inhibitors. Pancreatitis, sometimes severe or fatal, is a known risk associated with DPP-4 inhibitors like sitagliptin. Patients should be immediately evaluated if symptoms suggestive of these conditions develop, and treatment discontinuation may be required. Healthcare professionals must carefully consider these serious risks when prescribing ertugliflozin + sitagliptin and provide comprehensive patient counseling.
- Several critical warnings are associated with ertugliflozin + sitagliptin.
- Diabetic ketoacidosis (DKA), a life-threatening condition, has been reported in SGLT2 inhibitor users, including ertugliflozin, sometimes with only moderately elevated glucose levels.
- Risk factors include acute illness, reduced caloric intake, dehydration, or concurrent alcohol use.
- Acute kidney injury, sometimes requiring hospitalization and dialysis, has also been observed.
- Volume depletion and hypotension can occur, especially in elderly patients, those with impaired renal function, or those on diuretics.
- Necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious infection, has been reported with SGLT2 inhibitors.
- Pancreatitis, sometimes severe and fatal, has been observed with DPP-4 inhibitors like sitagliptin.
- Hypersensitivity reactions, severe and disabling arthralgia, and bullous pemphigoid are also recognized risks.
- Healthcare providers should assess renal function before and during treatment, monitor for signs of volume depletion, and educate patients on symptoms of DKA, Fournier's gangrene, and pancreatitis.
- Discontinuation of the drug may be necessary in case of serious adverse events.
How it Works (Mechanism of Action)
The therapeutic efficacy of ertugliflozin + sitagliptin stems from the complementary actions of its two active components. Ertugliflozin is a highly selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules. By inhibiting SGLT2, ertugliflozin reduces glucose reabsorption from the glomerular filtrate, leading to increased urinary glucose excretion (glucosuria) and consequently, a reduction in plasma glucose concentrations. This mechanism is independent of insulin secretion and sensitivity. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released by the intestine in response to food and play a vital role in glucose homeostasis by enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon secretion from pancreatic alpha cells. The combined action provides synergistic improvements in glycemic control through both insulin-dependent and insulin-independent pathways.
Commercial Brands (Alternatives)
No other brands found for this formula.